Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study
NCT ID: NCT03254914
Last Updated: 2024-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
3554 participants
OBSERVATIONAL
2017-08-09
2019-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Site
Measure Clinic Blood Pressure
No interventions assigned to this group
Test Site
Measure Clinic Blood Pressure and Home Blood Pressure
Home Blood Pressure
Measure Home Blood Pressure
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Home Blood Pressure
Measure Home Blood Pressure
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male and female over the age of 19
* Hypertensive patients receiving two or more concomitant anti-hypertensive agents including fimasartan
Exclusion Criteria
* Diabetic nephropathy patients taking angiotensin-converting enzyme inhibitor.
* Severe renal disorder
* Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
* Medical history with hypersensitivity to Fimasartan
* Pregnant women or lactating female.
* Participate in another clinical trial.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boryung Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul national university hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Choi JY, Kim KI, Kim CH. Effect of home blood pressure monitoring for blood pressure control in hypertensive patients taking multiple antihypertensive medications including fimasartan (the FORTE study). Clin Hypertens. 2020 Dec 15;26(1):24. doi: 10.1186/s40885-020-00154-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR-FMS-OS-403
Identifier Type: -
Identifier Source: org_study_id